Viome收购 Circulate Health，打通早期诊断、精准营养与治疗之间的闭环-动脉网

Viome Acquires Circulate Health, Closing the Loop Between Early Diagnostics, Precision Nutrition, and Treatment

CISION 等信源发布 2026-08-12 20:58



可切换为仅中文







Together, the two companies give physicians a single platform to measure biological insights, deliver personalized interventions, and demonstrate health outcomes over time, now backed by a nationwide clinical network of over 200 clinics.

两家企业携手为医生提供一个统一平台，用于衡量生物学洞察、实施个性化干预措施，并长期展示健康结果；该平台如今已得到覆盖全国、拥有200多家诊所的临床网络的支持。

BELLEVUE, Wash.

华盛顿州贝尔维尤

，

Aug. 12, 2026

2026年8月12日

/PRNewswire/ --

/美通社/ --

Viome Life Sciences

维奥梅生命科学

, a leading preventive health technology company, today announced it has acquired

，一家领先的预防性健康科技公司，今日宣布已收购

Circulate Health

循环健康

, a pioneer of therapeutic plasma exchange (TPE) outside the hospital setting. Circulate's protocols target healthspan and chronic disease, and include a proprietary approach to reducing microplastics in the body.

，院外治疗性血浆置换（TPE）的先驱。Circulate 的方案旨在延长健康寿命并应对慢性疾病，其中包括一种减少体内微塑料的专有方法。

The move unites Viome's molecular diagnostic and precision nutrition platform with Circulate's physician-guided therapeutic plasma exchange and its nationwide network of clinical partners.

此举将Viome的分子诊断与精准营养平台，与Circulate的医生指导治疗性血浆置换及其全国临床合作伙伴网络整合在一起。

继续阅读

Viome and Circulate give physicians a single platform to measure, treat, and demonstrate outcomes.

Viome 和 Circulate 为医生提供了一个统一的平台，用于测量、治疗并展示疗效。

Post this

发布此内容

'We don't accept that declining health is inevitable,' said Naveen Jain, founder of Viome. 'The future of medicine isn't treating disease. It's making health something you can measure and improve, year after year. Acquiring Circulate is the latest step in giving patients not just answers, but precision intervention.

“我们不接受健康状况下滑是不可避免的这一观点，”Viome 创始人纳文·贾恩表示。“医学的未来不在于治疗疾病，而在于让健康成为可以逐年测量和改善的状态。收购 Circulate 是我们迈向为患者不仅提供答案，更提供精准干预的最新一步。”

That's what longevity medicine should be, and we're just getting started.'.

“这就是长寿医学应有的样子，而我们才刚刚起步。”

Viome has always been about action, not insight alone, translating what its diagnostics reveal into personalized, targeted interventions. But the range of actions available to clinicians has been limited

Viome 始终注重行动，而非仅提供洞察，将其诊断结果转化为个性化的精准干预措施。然而，临床医生可用的干预手段一直有限。

。

As the science of measuring biological aging, inflammation, metabolism, and the microbiome advances, the opportunity is to widen what a clinician can actually do with that information.

随着测量生物衰老、炎症、代谢和微生物组的科学不断进步，机会在于扩大临床医生利用这些信息所能实际开展的工作范围。

Circulate's nationwide network of partner clinics, staffed by Circulate's expert-trained nurses, delivers physician-guided therapeutic plasma exchange under precise clinical protocols. Paired with Viome's precision diagnostics, the combination advances Viome's vision of a single connected system where clinicians can measure, act, and measure again.

Circulate 的全国合作诊所网络由经过其专家培训的护士组成，在严格的临床方案下提供由医生指导的治疗性血浆置换。与 Viome 的精准诊断相结合，这一组合推动了 Viome 构建单一互联系统的愿景，使临床医生能够测量、干预并再次测量。

That shift turns episodic care into measurable, longitudinal outcomes..

这一转变将 episodic care 转化为可衡量的纵向结局。

Dr. Brad Younggren, MD, co-founder and CEO of Circulate Health, will join Viome as President of its newly formed clinical group, Viome PRO.

布拉德·杨格伦医学博士（Dr. Brad Younggren, MD），Circulate Health 的联合创始人兼首席执行官，将加入 Viome，担任其新成立的临床集团 Viome PRO 的总裁。

'Longevity medicine has reached an inflection point,' said Younggren

“长寿医学已到达拐点，”扬格伦表示

。

'We can measure more about human biology than ever before, and the field now has real, proven ways to act on those insights. What drew me to Viome is a shared belief that this field advances by bringing the right capabilities together. Precision plasma exchange alongside Viome's molecular platform gives clinicians a broader, more credible way to practice longevity medicine today, and that's a meaningful step forward for patients.'.

“如今，我们对人类生物学的测量能力达到了前所未有的水平，该领域现已拥有切实可行且经证实的方法，可将这些洞察转化为实际行动。我之所以被Viome吸引，是因为我们共同坚信，通过整合恰当的技术能力，能够推动这一领域不断前进。将精准血浆置换技术与Viome的分子平台相结合，为临床医生提供了更广泛、更可信的长寿医学实践方式，这对患者而言是具有重要意义的一步。”

Therapeutic plasma exchange is an established medical procedure, used in hospitals for more than 50 years to treat a range of autoimmune and neurological conditions. Circulate Health has helped pioneer its application in longevity medicine by developing precise clinical protocols and contributing to a growing body of peer-reviewed research..

治疗性血浆置换是一项成熟的医疗程序，已在医院中应用超过50年，用于治疗多种自身免疫性和神经系统疾病。Circulate Health通过开发精确的临床方案并推动同行评审研究的积累，率先将其应用于长寿医学领域。

Most recently, a study published in the

最近，一项发表在

Journal of Clinical Apheresis

临床分离术杂志

(2026) found that Circulate Health's TPE procedure was associated with measurable reductions in circulating microplastic particles in the blood of patients with elevated baseline levels. Earlier research, published in

（2026年）发现，Circulate Health 的 TPE 手术与基线水平升高的患者血液中循环微塑料颗粒的可测量减少有关。早期研究发表于

Aging Cell

衰老细胞

(2025), reported that Circulate's plasma exchange protocol was associated with an average 2.6-year reduction in biological age across a panel of molecular biomarkers. Together, these studies reflect a shared commitment held by both Circulate and Viome

（2025年）报告称，Circulate的血浆置换方案与一组分子生物标志物所测得的生物学年龄平均减少2.6年相关。这些研究共同反映了Circulate和Viome所秉持的共同承诺。

，

to advancing science through rigorous clinical research.

致力于通过严谨的临床研究推动科学进步。

Circulate Health was founded by Dr. Brad Younggren and Dr. Eric Verdin, CEO of the Buck Institute.

Circulate Health 由布拉德·杨格伦博士和巴克研究所首席执行官埃里克·维尔丁博士共同创立。

With Circulate, Viome advances its long-term vision for a comprehensive precision longevity platform, one that unites diagnostics, personalized interventions, and clinical delivery, and can evolve as new tests, therapies, and innovations emerge. It is a more connected approach to preventive health: less about any single test or treatment, and more about the system that ties them together and demonstrates they work..

通过 Circulate，Viome 推进其打造全面精准长寿平台的长期愿景。该平台集诊断、个性化干预和临床服务于一体，并能随着新检测、新疗法及新技术的出现而不断演进。这是一种更为互联的预防性健康方法：不再侧重于单一的检测或治疗，而是着眼于将这些要素有机结合并验证其有效性的整体系统。

About Viome Life Sciences

关于 Viome 生命科学

Viome Life Sciences was founded in 2016 with a mission to make illness optional by predicting and preventing chronic diseases, cancers, and aging through a deeper understanding of an individual's biology at a molecular level. The Viome PRO division leverages proprietary RNA sequencing technology, exclusively licensed from Los Alamos National Laboratory, and AI to develop non-invasive early detection tests for high-mortality cancers and chronic diseases..

Viome Life Sciences 成立于2016年，其使命是通过在分子层面更深入地理解个体生物学特征，预测并预防慢性疾病、癌症和衰老，从而使疾病成为可选项。Viome PRO 部门利用从洛斯阿拉莫斯国家实验室独家许可的专有RNA测序技术以及人工智能，开发用于高死亡率癌症和慢性疾病的无创早期检测测试。

References

参考文献

Fuentealba M, Kiprov D, Schneider K, et al.

富恩特阿尔巴 M，基普罗夫 D，施耐德 K，等

Multi-Omics Analysis Reveals Biomarkers That Contribute to Biological Age Rejuvenation in Response to Single-Blinded Randomized Placebo-Controlled Therapeutic Plasma Exchange.

多组学分析揭示有助于生物年龄年轻化的生物标志物：来自单盲随机安慰剂对照治疗性血浆置换的响应

Aging Cell.

衰老细胞。

2025;24(8).

Weinstein R, Yuksel ZS, Anderson C, et al.

温斯坦 R，于克塞尔 ZS，安德森 C，等。

Can Plasma Exchange Be Used to Lower the Circulating Burden of Microplastics in Human Patients?

血浆置换能否用于降低人类患者体内微塑料的循环负荷？

Journal of Clinical Apheresis.

《临床血液分离杂志》

2026;41(3):e70135.

Media Contact